Articles

Molecular targeting of the UDP-glucuronosyltransferase enzymes in high-eukaryotic translation initiation factor 4E refractory/relapsed acute myeloid leukemia patients: a randomized phase II trial of vismodegib, ribavirin with or without decitabine

Jewish General Hospital and McGill University 3755 Cote Ste Catherine, Montreal, Quebec H3T1E2
Institute for Research in Immunology and Cancer and Department of Pathology and Cell Biology, University of Montreal, Montreal, Quebec
CEMTL installation Maisonneuve Rosemont, 5415 boul. de l’Assomption, Montreal H1T 2M4
Institute for Research in Immunology and Cancer and Department of Pathology and Cell Biology, University of Montreal, Montreal, Quebec
Institute for Research in Immunology and Cancer and Department of Pathology and Cell Biology, University of Montreal, Montreal, Quebec
Jewish General Hospital and McGill University 3755 Cote Ste Catherine, Montreal, Quebec H3T1E2
Jewish General Hospital and McGill University 3755 Cote Ste Catherine, Montreal, Quebec H3T1E2
Jewish General Hospital and McGill University 3755 Cote Ste Catherine, Montreal, Quebec H3T1E2
Princess Margaret Cancer Centre, Division of Medical Oncology and Hematology, Toronto, Ontario
Institute for Research in Immunology and Cancer and Department of Pathology and Cell Biology, University of Montreal, Montreal, Quebec
Vol. 108 No. 11 (2023): November, 2023 https://doi.org/10.3324/haematol.2023.282791